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244A disintegrin and metalloproteases (ADAMs) are a family of proteins that have been
reported to be involved in several inflammatory conditions. We examined the secre-
tion of ADAM-10 in biological fluids from patients with rheumatoid arthritis (RA) and
the role it plays in monocyte migration. ADAM-10 levels were measured using
enzyme-linked immunosorbent assays and immunofluorescence. To examine the
role of ADAM-10 in RA synovial fluids (SFs), we studied THP-1 (human acute
monocyte leukemia cell line) and monocyte chemotaxis. To determine whether
ADAM-10 plays a role in cell proliferation in the RA synovium, we assayed the prolif-
eration of ADAM-10 small interfering RNA (siRNA)-transfected RA fibroblast-like syn-
oviocytes (FLSs). The ADAM-10 level in RA serum was significantly higher than that in
normal serum and was correlated with a disease activity score of 28. ADAM-10–
depleted RA SFs showed a decrease in THP-1 and monocyte migratory activity
compared with that of sham-depleted controls. ADAM-10 siRNA inhibited monocyte
adhesion to RA FLSs. Finally, blocking ADAM-10 secretion in RA FLSs resulted in
decreased production of fractalkine/CX3CL1 and vascular endothelial cell growth
factor. These data indicate that ADAM-10 plays a role in monocyte migration in RA
and suggest that targeting ADAM-10 may provide a method of decreasing inflam-
mation and potentially treating other inflammatory diseases. (Translational Research
2015;166:244–253)Abbreviations: ADAMs ¼ A disintegrin and metalloproteases; DAS28 ¼ disease activity score of
28; FLS¼ fibroblast-like synoviocyte; OA¼ osteoarthritis; RA¼ rheumatoid arthritis; SFs¼ synovial
fluids; STs ¼ synovial tissuesne, Showa University School of
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.02.005INTRODUCTIONR heumatoid arthritis (RA) is characterized bysynovial inflammation in multiple joints andirreversible joint destruction in the absence of
treatment.1 The inflammatory cells involved in the path-
ogenesis of RA are synovial tissue (ST) macrophages,
which produce several cytokines and chemokines.2,3
Determining the cytokine and chemokine networks in
RA poses an important challenge for furthering our
understanding of the pathogenesisof RA.4-7 The
therapeutic management of RA has changed
dramatically in recent decades. One of the most
effective current therapies is designed to block tumor
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Background
A disintegrin and metalloprotease 10 (ADAM-10)
has been reported to be the enzyme responsible for
the release of a number of cytokine. ADAM-10
was expressed in rheumatoid arthritis (RA) syno-
vial tissues and mediated angiogenesis.
Translational Significance
We demonstrate the expression of ADAM-10 in
RA serum and synovial fluids. ADAM-10 was
significantly correlated with disease activity.
Blocking expression of ADAM-10 in RA synovial
fibroblasts reduced cell adhesion and proliferation,
because of inhibition of adhesion and proinflam-
matory mediator production. These results indicate
the importance of ADAM-10 in RA and suggest
that targeting ADAM-10 may be important in
combating RA.
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Volume 166, Number 3 Isozaki et al 245necrosis factor a (TNF-a).8 However, despite the suc-
cess of blocking TNF-a, not all patients with RA
respond adequately to anti–TNF-a therapy.9-11 Trials
using antibodies to other chemokines or chemokine
inhibitors have been conducted in animal models of
arthritis. Specific chemokine or chemokine receptor
targeting may also be available in the near future,
highlighting the possible importance of other
molecules for RA treatment.
A disintegrin and metalloproteases (ADAMs) are a
family of proteases that liberate a variety of cell
surface-expressed proteins.12,13 ADAM-10 has been
reported to be responsible for the release of several
chemokines, such as fractalkine/CX3CL1 and
CXCL16.14,15 Yang et al16 reported the presence of
ADAM-10 in human aortic smooth muscle cell superna-
tant. The researchers also demonstrated that overexpres-
sion of ADAM-10 in human aortic smooth muscle cells
induced a significant stepwise increase in migration in a
Boyden chamber assay. We previously showed that
ADAM-10 was expressed in RA STs and mediated
angiogenesis.17 However, the role of ADAM-10 in RA
inflammation is not yet clear.
Here, we demonstrate the secretion of ADAM-
10 in RA biological fluids and its role in inflam-
mation and monocyte recruitment. We also show
that blocking ADAM-10 in fibroblast-like synovio-
cytes (FLSs) reduced cell adhesion and cytokine
production.MATERIALS AND METHODS
Patients. RA STs were obtained from patients under-
going arthroplasty or synovectomy. RA and osteoar-
thritis (OA) synovial fluids (SFs) were obtained from
patients. All specimens were obtained with informed
consent and collected following approval from the
Showa University Institutional Review Board.
Cell culture. Fresh STs were minced and digested in
tissue enzyme digestion solution as described previ-
ously.18 The FLSs were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum
(FBS). Cells were seeded in 6-well plates (BD
Biosciences, Bedford, Massachusetts) at a density of
1 3 105 cells per well and were maintained in
complete medium. After overnight serum starvation,
the cells were treated with TNF-a (R&D Systems,
Minneapolis, Minnesota).
THP-1 cells (human acute monocytic leukemia cell
line) were purchased from the American Type Culture
Collection (Manassas, Virginia). THP-1 cells were
cultured in RPMI 1640 medium supplemented with
10% FBS.
Enzyme-linked immunosorbent assay of ADAM-10,
fractalkine/CX3CL1, and vascular endothelial growth
factor. Enzyme-linked immunosorbent assays (ELISAs)
were performed as described previously.19 The level of
ADAM-10 in serum and SFs was measured following
the manufacturer’s protocol (My BioSource, San
Diego, California). We used My BioSource ADAM-10
ELISA kit #MBS704324. The detection range was
7.8–500 pg/mL, and the minimum detectable dose of
ADAM-10 was less than 1.95 pg/mL. Fractalkine/
CX3CL1 and vascular endothelial growth factor
(VEGF) in RA FLS-conditioned medium were
measured using an R&D Duo kit (R&D Systems).
Immunofluorescence. To measure the secretion of
ADAM-10 in RA ST synovial fibroblasts, mouse anti-
human collagen-1, and rabbit anti–ADAM-10 were
used as primary antibodies. RA FLSs were plated at a
density of 20,000 per well in 8-well Labtek chamber
slides. The next day, the cells were washed with
phosphate-buffered saline (PBS) and were fixed. RA ST
slides were fixed with cold acetone for 20 minutes and
were washed with PBS. Then, the slides were blocked
with 20% FBS and 5% donkey serum for 1 hour at
37C. Mouse anti–collagen-1 antibody (1 mg/mL;
Abcam #ab6308, Cambridge, Massachusetts) and rabbit
anti-human ADAM-10 antibody (10 mg/mL; Abcam
#ab1977) were used. Alexa Fluor 488–conjugated
donkey anti-rabbit antibody and Alexa Fluor 555–
conjugated donkey anti-mouse antibody were purchased
from Life Technologies (Carlsbad, California). For
nuclear staining, 40,6-diamidino-2-phenylindole was
used. Images were taken at3400 magnification.
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reaction of RA FLSs. RNA extraction and quantitative po-
lymerase chain reaction (qPCR) were performed as pre-
viously described.17 Total RNA was isolated from
human RA FLSs using RNeasy mini RNA isolation
kits (Qiagen, Valencia, California) in accordance with
the manufacturer’s protocol. Following isolation, the
RNA was quantified and checked for purity using
a spectrophotometer (Nanodrop Technologies,
Wilmington, Delaware). Complementary DNA was
prepared using a Reverse-IT MAX first-strand
synthesis kit (Abgene, Rochester, New York) as per
the manufacturer’s protocol. ADAM-10 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
primer pairs were purchased from Integrated DNA
Technologies (Coralville, Iowa). The following
primers were used: ADAM-10 forward, 50-AATGGA
TTGTGGCTCATTGGTGGG-30; ADAM-10 reverse,
50-TGGAAGTGGTTTAGGAGGAGGCAA-30; GAPDH
forward, 50-GCTCACTGGCATGGCCTTCCG-30; and
GAPDH reverse, 50-GTGGGCCATGAGGTCCAC
CAC-30. ADAM-10 messenger RNA (mRNA) was
measured by real-time qPCR with the use of SYBR
Green/ROX master mix (SABiosciences, Frederick,
Maryland) on an Mx3005P thermal cycler (Stratagene,
Santa Clara, California). The ratio of each mRNA
relative to the GAPDH mRNAwas calculated using the
DD threshold cycle method. All samples were run in
duplicate and analyzed using Applied Biosystems
software (Life Technologies).
Neutralization of ADAM-10 in RA SFs. To determine the
role of ADAM-10 in RA SFs, RA SFs were depleted
using rabbit anti–ADAM-10. RA SFs (1:100 diluted
with PBS) were preincubated either with rabbit anti-
human ADAM-10 antibody (Abcam) or with an
equivalent amount of a corresponding control antibody
(nonspecific rabbit immunoglobulin G [IgG]) for
2 hours at 4C. Samples were mixed with protein A/G
agarose (Millipore, Billerica, Massachusetts) and rotated
overnight at 4C. Samples were centrifuged briefly to
pellet the ADAM-10-antibody-protein A/G complex,
and the ADAM-10–depleted SFs were collected.
Isolation of peripheral blood monocytes. Peripheral
blood monocytes were obtained from healthy individ-
uals. The mononuclear cells were isolated by centrifu-
gation on a Ficoll-Paque Plus (GE Healthcare Life
Sciences, Piscataway, New Jersey) density gradient,
after which the monocytes were separated by
centrifugation on a density gradient (1.068 g/mL;
Nycodenz, Nycomed AS Oslo, Norway).
In vitro THP-1 and monocyte chemotaxis assay. To
examine the bioactivity of ADAM-10 in RA SFs, we
performed THP-1 and monocyte chemotaxis assays.
Sham-depleted or ADAM-10–depleted RA SFs wereadded to the bottom wells of chambers, and a
polycarbonate 5-mm membrane was placed over the
reagents. THP-1 cells at 1 3 106 cells/mL or
monocytes at 2.5 3 106 cells/mL were added to the
top wells and incubated for 90 minutes. The
membranes were fixed in methanol and stained with
Protocol Hema 3 (Fisher Scientific, Pittsburgh,
Pennsylvania). Each test group was assayed in
quadruplicate. Three high-power (3400) fields were
counted in each replicate well, and the results are
expressed as cells per high-power fields.
Transfection of RA FLSs with ADAM-10 small interfering
RNA. RA FLSs were seeded in 6-well plates at a
density of 1 3 105 cells per well. Small interfering
RNA (siRNA; 100 nM) against ADAM-10 or control
siRNA was mixed with TransIT-TKO transfection
reagent (Mirus, Madison, Wisconsin) according to the
manufacturer’s instructions and overlaid on the cells.
The cells were incubated with the siRNA-TransIT-
TKO for 24 hours at 37C. The ADAM-10 and
control siRNAs were purchased from Life
Technologies. Knockdown of ADAM-10 secretion
was confirmed using Western blotting. Membranes
were probed with rabbit anti-human ADAM-10
antibody (Abcam) and antiactin.
In vitro cell adhesion assay. The adhesion of THP-1
cells to control siRNA-treated or ADAM-10 siRNA-
treated RA FLSs grown to confluence in 96-well
plates was examined. RA FLSs were serum-starved
overnight. The next day, the cells were treated with
TNF-a (10 ng/mL) for 24 hours. THP-1 cells were
collected and labeled with Calcein AM fluorescent
dye (5 mM; Life Technologies) for 30 minutes. After
being washed twice, 1 3 105 THP-1 cells were
added to each well and incubated for 30 minutes at
room temperature. Nonadherent cells were washed
away, and the fluorescence was measured using a
Synergy HT fluorescence plate reader (BioTek
Instruments).
Cell surface ELISA for adhesion molecule
expression. Control siRNA-transfected or ADAM-10
siRNA-transfected RA FLSs (1 3 105/well) were
seeded in 96-well plates. Confluent RA FLSs were
serum-starved overnight before stimulation with TNF-
a (10 ng/mL) for 24 hours. The cells were fixed with
3.7% formalin in PBS for 30 minutes. Mouse anti-
human antibodies specific for intercellular adhesion
molecule 1 (ICAM-1, 10 mg/mL; R&D systems) or
vascular cell adhesion molecule 1 (VCAM-1) were
incubated for 1 hour. Subsequently, biotinylated
anti-mouse antibody and streptavidin-horseradish
peroxidase were added for 1 hour, and the concen-
tration in the samples was measured at 450 nm after
reaction with the tetramethylbenzidine substrate.
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Fig 1. ADAM-10 is expressed in RA. (A) RA serum containedmore ADAM-10 than did NL serum. (B) RA SFs con-
tained more ADAM-10 than did OA SFs. (C) The level of ADAM-10 in RA serum showed a significant positive cor-
relation with DAS28 (n5 number of patients). ADAM, A disintegrin and metalloprotease; DAS28, disease activity
score of 28; OA, osteoarthritis; RA, rheumatoid arthritis; SFs, synovial fluids.
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Fig 2. ADAM-10 in RA SFs has monocyte chemotactic activity. (A) THP-1 migration was measured in a chemo-
taxis assay using sham-depleted or ADAM-10–depleted RA SFs. ADAM-10 depletion resulted in a 56 6 9%
(n 5 5) reduction in RA SF-induced THP-1 migration. (B) Monocyte migration was measured in a chemotaxis
assay using sham-depleted or ADAM-10–depleted RA SFs. ADAM-10 depletion resulted in a 53 6 7%
(n 5 6) reduction in RA SF-induced monocyte migration (n 5 number of RA patients). ADAM, A disintegrin
and metalloprotease; hpfs, high-power fields; RA, rheumatoid arthritis; SFs, synovial fluids.
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Fig 3. ADAM-10 is expressed in RA synovial fibroblasts. (A) The upper-left panel shows ST stained with rabbit
anti–ADAM-10. The upper-middle panel shows ST stained with mouse anti–collagen-1. The upper-right panel
shows the merging of the upper-left panel and the upper-middle panel. The lower-left panel shows ST stained
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dent’s t test assuming equal variances. The relationship
between ADAM-10 in RA serum and a disease activity
score of 28 (DAS28) was evaluated using Spearman’s
rank correlation. Data are reported as the
mean 6 standard error of the mean (SEM). P values
less than 0.05 were considered statistically significant.RESULTS
Levels of ADAM-10 in RA serum and SFs. We examined
the levels of ADAM-10 in RA biological fluids. We
measured ADAM-10 in normal (NL) and RA serum
using ELISA. We found that ADAM-10 was expressed
in NL serum (n 5 34) and that its expression was
significantly increased in RA serum (n 5 90) (85 6 33
and 450 6 44 pg/mL, respectively, Fig 1, A). We also
measured the ADAM-10 levels in OA and RA SFs.
We found that the ADAM-10 concentration in RA
SFs (n 5 10) was significantly increased compared
with that in OA SFs (n 5 7) (727 6 144 and
255 6 42 pg/mL, respectively, Fig 1, B). To determine
whether ADAM-10 contributes to the development of
inflammation in RA, we examined the relationship
between ADAM-10 and DAS28. DAS28 is a
quantitative measure of disease activity and measures
patient global health (patient self-assessment), tender
joint-counts and swollen joint-counts (up to 28), and the
erythrocyte sedimentation rate. We found that the level
of ADAM-10 in RA serum showed a weak but
significant positive correlation with DAS28 (r 5 0.33,
P , 0.05, n 5 90 patients, Fig 1, C). The level of
ADAM-10 in RA serum also showed a very weak
positive correlation with erythrocyte sedimentation rate
(r 5 0.28, P , 0.05). These results suggest that the
level of ADAM-10 in RA serum is weakly correlated
with disease activity.
Function of ADAM-10 in RA SFs. To demonstrate the
function of ADAM-10 in RA SFs, SFs depleted of
ADAM-10 were assayed for their ability to induce
monocyte chemotaxis. Because RA SF was potently
chemotactic for monocytes, we performed in vitro
THP-1 and monocyte chemotaxis assays using sham-
or ADAM-10–depleted RA SFs. We found thatwith rabbit IgG. The lower-middle panel shows ST stainedw
ing of the lower-left panel and the lower-middle panel. The
lining cells (original magnification 3400). The arrows indi
panel shows RA FLS stained with rabbit anti–ADAM-10.
IgG. The right panel shows RA FLS stained with rabbi
3400). (C) TNF-a upregulated ADAM-10 mRNA in RA
at 4 hours (n 5 number of replicates). ADAM, A disintegr
cyte; GAPDH, glyceraldehyde 3-phosphate dehydrogenase
mRNA, messenger RNA; NS, nonstimulated; ST, synovial
=ADAM-10–depleted RA SFs showed a 56 6 9%
(n 5 5 patients) decrease in THP-1 migratory activity
compared with that of sham-depleted controls
(number of THP-1 cells that migrated 6 SEM; 7 6 1
and 17 6 3 cells migrated, respectively, P , 0.05,
Fig 2, A). In addition, ADAM-10–depleted RA SFs
showed a 53 6 7% (n 5 6 patients) decrease in
monocyte chemotactic activity compared with that of
sham-depleted controls (number of monocytes
migrated 6 SEM; 19 6 3 and 43 6 6, respectively,
P , 0.05, Fig 2, B).
Expression of ADAM-10 in RA ST lining cells and RA
FLS. To determine whether ADAM-10 was expressed
in RA ST lining cells and FLS, immunofluorescence
was performed. ADAM-10– and collagen-1–positive
cells can be observed in RA ST (Fig 3, A), indicating
that ADAM-10 was expressed in RA synovial lining
cells. We then examined FLS isolated from STs, and
immunofluorescence was performed. We found that
ADAM-10 was expressed in RA FLS (Fig 3, B). TNF-
a upregulated ADAM-10 mRNA in RA FLS at
1 hour, and the mRNA levels were increased at
4 hours (Fig 3, C).
Blocking ADAM-10 in RA FLS reduces THP-1
adhesion. To further examine the function of ADAM-
10 in RA FLS, we used RA FLSs that were
transfected with siRNA directed against ADAM-10.
Specific knockdown of ADAM-10 was confirmed by
Western blotting, and the ADAM-10 protein levels
were decreased (Fig 4, A). To determine whether
ADAM-10 mediates leukocyte adhesion to RA FLS,
we performed in vitro adhesion assays. We found that
the adhesion of THP-1 cells to ADAM-10 siRNA-
transfected RA FLS in response to TNF-a was
significantly decreased compared with that in control
siRNA-transfected RA FLS (Fig 4, B). In addition, we
performed a cell surface ELISA to determine whether
cell adhesion molecules were decreased on the cell
surface of ADAM-10 siRNA-transfected RA FLS. We
found that the VCAM-1 on TNF-a–stimulated
ADAM-10 siRNA-transfected RA FLS was decreased
compared with that on the control siRNA-transfected
RA FLS (Fig 4, C). However, ICAM-1 on TNF-a–
stimulated ADAM-10 siRNA-transfected RA FLS wasith mouse IgG. The lower-right panel shows themerg-
yellow colour indicates ADAM-10 associated with ST
cate ADAM-10–positive ST lining cells. (B) The left
The middle panel shows RA FLS stained with rabbit
t anti–smooth muscle actin (original magnification
FLS at 1 hour, and the mRNA levels were increased
in and metalloprotease; FLS, fibroblast-like synovio-
; IgG, immunoglobulin G; RA, rheumatoid arthritis;
tissue; TNF-a, tumor necrosis factor a.
Fig 4. ADAM-10 expression was decreased by the application of siRNA against ADAM-10 in RA FLS. Cells
were stimulated with TNF-a (10 ng/mL) for 24 hours. (A) ADAM-10 expression in ADAM-10 siRNA-treated
RA FLS and control siRNA-treated RA FLS. (B) ADAM-10 mediates the adhesion of THP-1 cells to RA FLS.
The adhesion of THP-1 cells to NS- or TNF-a–stimulated ADAM-10 siRNA-transfected RA FLS was signifi-
cantly decreased compared with the adhesion of THP-1 cells to NS- or TNF-a–stimulated control siRNA-
transfected cells. (C) The VCAM-1 expression on TNF-a–stimulated ADAM-10 siRNA-transfected RA FLS
was significantly decreased compared with that on TNF-a–stimulated control siRNA-treated RA FLS
(n 5 number of RA patients). ADAM, A disintegrin and metalloprotease; FLS, fibroblast-like synoviocyte;
NS, nonstimulated; RA, rheumatoid arthritis; siRNA, small interfering RNA; TNF-a, tumor necrosis factor a;
VCAM-1, vascular cell adhesion molecule 1.
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transfected RA FLS (data not shown). These results
confirm that ADAM-10 inhibition regulates TNF-a-
induced fibroblast adhesion and VCAM-1 but not
ICAM-1 expression.
Blocking ADAM-10 in RA FLS inhibits the expression of
proinflammatory mediators. We found that the secretion
of fractalkine/CX3CL1 and VEGF in medium condi-
tioned by TNF-a–stimulated, ADAM-10 siRNA-
transfected RA FLSs was significantly decreased
compared with the secretion in medium conditioned
by control siRNA-transfected RA FLSs (Fig 5, A and
B). These results indicate that ADAM-10 in RA FLS
regulates cell adhesion and proliferation by secreting
proinflammatory cytokines.
DISCUSSION
Fractalkine/CX3CL1 and CXCL16 are strong chemo-
tactic chemokines, and these molecules mediateinflammatory cell infiltration, cell adhesion, and angio-
genesis.20-23 Fractalkine/CX3CL1 and CXCL16 are
membrane-spanning molecules expressed on the cell
surface and exist in both soluble and membrane-
bound forms. Both chemokines can be cleaved by
ADAM-10 and ADAM-17.15,24,25 ADAM-10 is a prote-
ase with a range of substrates that plays roles in cancer
proliferation and inflammation. We previously reported
for the first time that ADAM-10 was overexpressed in
RA ST ECs compared with the expression in OA or
NL STs.17 On the basis of this, we sought to investigate
the expression and regulation of ADAM-10 in RA
inflammation. The present study demonstrates that
ADAM-10 is expressed in RA serum and is highly
increased compared with the level in NL serum. Wang
et al26 reported that the expression of ADAM-10 in
gastric cancer was significantly related to lymph node
and distant metastasis and suggested that ADAM-10
may be a useful marker to predict tumor progression
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Fig 5. ADAM-10 expression was decreased by the application of
siRNA against ADAM-10 in RA FLS. Cells were stimulated with
TNF-a (10 ng/mL) for 24 hours. (A) Fractalkine/CX3CL1 expression
in ADAM-10 or control siRNA-treated RA FLS. (B) VEGF expression
in ADAM-10 or control siRNA-treated RA FLS. Mean values are
given together with the standard error of the mean (n5 number of rep-
licates). ADAM, A disintegrin and metalloprotease; FLS, fibroblast-
like synoviocyte; RA, rheumatoid arthritis; siRNA, small interfering
RNA; TNF-a, tumor necrosis factor a; VEGF, vascular endothelial
growth factor.
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ADAM-10 in RA serum is significantly positively
correlated with DAS28. These results indicate that the
level of ADAM-10 in serum may be a biomarker of dis-
ease activity in RA. In addition, we show that ADAM-
10 is present in RA SFs and its level is significantly
increased compared with that in OA SFs. Our findings
support the notion that ADAM-10 may play an impor-
tant role in RA pathophysiology.Oh et al27 reported highly increased expression of
ADAM-10 in psoriatic skin compared with NL skin.
Schulz et al28 showed that ADAM-10 actively plays a
role in the thrombin-induced decrease in EC-EC inter-
actions. We previously reported an indirect role of
ADAM-10 in EC chemotaxis but not a direct role. We
found that ADAM-10 was overexpressed in RA serum
and SFs. Because of these results, we sought to deter-
minewhether ADAM-10 in RA SFs has chemotactic ac-
tivity. We showed that RA SFs depleted of ADAM-10
induced less THP-1 cell migration compared with that
in sham-depleted RA SFs. We also showed that RA
SFs depleted of ADAM-10 induced less monocyte
migration compared with that in sham-depleted RA
SFs, suggesting that ADAM-10 may have an important
function in RA inflammation. Compared with previous
results, the ADAM-10 in RA SFs had greater monocyte
chemotactic ability. These results suggested that
ADAM-10 in RA SF may differ from recombinant
ADAM-10.
We next focused on ADAM-10 in RA synovial fibro-
blasts. We found that ADAM-10 was expressed on RA
ST lining cells and FLS. ADAM-10 transcripts detected
by real-time qPCR were promptly upregulated by TNF-
a stimulation. These results indicate that ADAM-10 has
a role in inflammation associated with RA. We then hy-
pothesized that ADAM-10mediates monocyte adhesion
to RA FLS and fibroblast proliferation in RA. We and
others previously reported that ADAM-10 plays a role
in angiogenesis in RA and some cancers.17,29,30 In this
study, we clearly demonstrate that the adhesion of
myeloid THP-1 cells to ADAM-10 siRNA-transfected
RA FLS was significantly decreased compared with
that in control siRNA-transfected RA FLS. The THP-
1 cell adhesion index was decreased after the ADAM-
10 production was blocked in RA FLS. However, the
number of adhered cells was low. These results may
suggest that other molecules are correlated with mono-
cyte adhesion in FLS. These findings are consistent with
those of Nagara et al,31 who showed that the shedding of
cell adhesion molecule 1, one of the multifunctional cell
adhesion molecules, was catalyzed by ADAM-10. Gra-
bowska et al32 also showed that endotherial growth
factor-associated shedding appears to be mediated by
ADAM-10 because knockdown of ADAM-10 results
in reduced shedding of soluble E-cadherin. However,
these groups did not examinewhich adhesion molecules
were differentially expressed during ADAM-10 inhibi-
tion in RA FLS. Here, we demonstrate that expression
of the cell surface adhesion molecule VCAM-1,
but not ICAM-1, was decreased on ADAM-10
siRNA-transfected RA FLS compared with that on con-
trol siRNA-transfected FLS. These findings indicate not
only that ADAM-10 in RA FLS is important for cell
Translational Research
252 Isozaki et al September 2015adhesion but also that these interactions may lead to the
activation of inflammatory cells and the perpetuation of
inflammation in the RA synovium.
Fractalkine/CX3CL1 and VEGF are well-known
proinflammatory molecules in RA and induce angio-
genesis and leukocyte recruitment.20,33,34 We found
that fractalkine/CX3CL1 and VEGF secretion were
upregulated by TNF-a in RA FLS. We also found that
the fractalkine/CX3CL1 and VEGF levels were
moderately decreased in medium conditioned by
TNF-a–stimulated ADAM-10 siRNA-transfected RA
FLS compared with that in medium conditioned by con-
trol siRNA-transfected FLS. We measured the produc-
tion of these cytokines in the cell supernatant but not
the total cytokine production. ADAM-10 may not only
have shedding activity but also produce cytokines. We
plan to address this issue in future work. These findings
suggest that ADAM-10 expressed in FLS plays an
important role in RA inflammation by contributing to
the production of proinflammatory mediators.
Our study demonstrated that ADAM-10 is overex-
pressed in RA biological fluids and its level was
correlated with RA disease activity. In addition, the
ADAM-10 in RA SFs has monocyte chemotactic prop-
erties. Blocking the expression of ADAM-10 in RA FLS
reduced the cell adhesion because of the inhibition of
adhesion and proinflammatory mediator production.
We propose that ADAM-10 plays roles in mediating
arthritis through this multistep process. Taken together,
these results indicate the importance of ADAM-10 in
RA and suggest that targeting ADAM-10may be impor-
tant for combating RA.ACKNOWLEDGMENTS
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